Reading ZNTL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZNTL free→Reading ZNTL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZNTL free→QuarterlyIQ Insights · ZNTL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director. Ms. Campbell's initial term is scheduled to expire at the Company's 2027 Annual Meeting of Stockholders, subject to the election and qual…
Other Events. On May 21, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology ("ASCO") Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. MUIR is a multi-part, open-label Phase 1b clinical trial evaluating azenosertib in combination with chemotherapy in patients with ovarian cancer. Part 1 evaluated azenosertib in combination with four chemotherap…
Results of Operations and Financial Condition. On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.
Other Events. On May 5, 2026, the Company announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer ("PROC"). ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 (…
Other Events. On April 9, 2026, the Company announced the selection of 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) as the optimal monotherapy dose of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer ("PROC") based on the prespecified interim data analysis from Part 2a of the Company's ongoing DENALI Phase 2 clinical trial. This dose will be carried forward in the ongoing DENALI Phase 2 clinical trial as well as the confirmatory ASPENOVA…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on March 26, 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: March 26, 2026 By: /s/ Julie Eastland Julie Eastland President and Ch…
Other Events. On January 6, 2026, the Company provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026. 2025 Accomplishments • Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib. The Company completed enrollment in Part 2a of the Phase 2 DENALI clinical trial (NCT05128825). Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of up to approxi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 15, 2025, Karan Takhar, who serves as Senior Managing Director and head of Life Sciences investing at Matrix Capital Management Company, L.P., resigned from his position as a member of the Board of Directors of Zentalis Pharmaceuticals, Inc. (the “Company”) and from all of the committees on which he served, effective immediately. Mr. Ta…
Other Events. On December 15, 2025 (the “Effective Date”), the Company entered into a Stock Purchase Agreement (the “Agreement”) with Matrix Capital Master Fund, LP (“Matrix”). Pursuant to the Agreement, the Company agreed to repurchase 7,500,000 shares of the Company’s common stock from Matrix at a price of $1.33 per share, representing a discount from the Company’s closing share price of $1.40 on December 12, 2025 (the “Repurchase”). The Repurchase closed on December 15, 2025. The Repurchas…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on November 10 , 2025 99.2 Corporate Presentation dated November 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: November 10, 2025…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 26, 2025, Andrea Paul informed the Board of Directors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) of her intent to resign as Chief Legal Officer and Corporate Secretary of the Company, effective as of September 18, 2025, in order to join the partnership of a large, international law firm. Following her resignation from…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on August 6, 2025 99.2 Corporate Presentation dated August 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: August 6, 2025 By: /s/…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on May 14, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: May 14, 2025 By: /s/ Julie Eastland Julie Eastland President and Chief…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on March 26, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: March 26, 2025 By: /s/ Julie Eastland Julie Eastland President and Ch…
Other Events. Azenosertib Development Plan for PROC Monotherapy On January 29, 2025, the Company announced that it would, as an initial matter, focus its development efforts for its WEE1 inhibitor product candidate, azenosertib, on patients with platinum-resistant ovarian cancer (“PROC”) whose tumors are Cyclin E1-positive as determined utilizing an immunohistochemistry (“IHC”) assay and Zentalis’ proprietary IHC cutoff. The Company has aligned with the U.S. Food and Drug Administration (“FDA…
Costs Associated with Exit or Disposal Activities. On January 22, 2025, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) approved a strategic restructuring of the Company to support execution of late-stage development for the Company’s WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a potentially registration-enabling azenosertib data readout from the Company’s DENALI Part 2 study, anticipated by the end of 2026. In connec…
Other Events. Following the strategic restructuring, the Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2027. Cautionary Note Regarding Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements in this Current Report that do not r…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.